Clinical Trial Update: Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial update of everolimus in combination with bortezomib for relapsed or refractory lymphoma, which has been terminated. The snippet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• Afinitor (everolimus)
• Velcade (bortezomib)

Snippet

Sponsor: Brian Hill, MD, PhD | Conditions: 714leukemia, Lymphoma | Phase 1 | Status: TERMINATED